# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Albert Einstein (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET012-SYN-TD
- Date: 1949-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clementine Ward, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of blood pressure, cholesterol, and smoking cessation. **S**

## History of present illness

Mr. Einstein returns about four months after his first visit. He has had no tobacco since his quit date and has had no cravings strong enough to need more than one or two lozenges a day for the past month; he still holds an empty pipe at his desk. His home blood pressure readings average 124/74 on amlodipine 5 mg and losartan 100 mg. He takes atorvastatin 40 mg and aspirin 81 mg without muscle aches, bruising, or bleeding. The back strain six weeks ago settled within ten days, and he has had no abdominal, back, or flank pain since. The lipid panel was not drawn in the first twelve weeks on atorvastatin, because no standing order was placed after the four-week visit; it was drawn today. **S**

| Element | Detail |
|---|---|
| Tobacco | Tobacco-free since the quit date; one or two lozenges a day |
| Blood pressure | Home average 124/74 |
| Medicines | Amlodipine 5 mg, losartan 100 mg, atorvastatin 40 mg, aspirin 81 mg; no side effects |
| Interval illness | Low back strain six weeks ago, resolved |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, fainting, or leg pain on walking |
| Gastrointestinal | Negative | No abdominal pain or black stools |
| Musculoskeletal | Negative | Back pain resolved; no muscle aches |
| Hematologic | Negative | No easy bruising or bleeding |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Losartan 100 mg oral tablet, one tablet daily **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Nicotine 7 mg/24 hour transdermal patch, one patch daily **S**
- Nicotine 2 mg lozenge as needed for cravings **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 79.4 kg; BMI 26.8 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.7 mmol/L; Creatinine: 1.1 mg/dL; eGFR: 70 mL/min/1.73 m²; Total cholesterol: 132 mg/dL; HDL cholesterol: 46 mg/dL; LDL cholesterol: 62 mg/dL; Triglycerides: 120 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 1.1 mg/dL at this visit **S**
- eGFR: 77 mL/min/1.73 m² at baseline, 70 mL/min/1.73 m² at this visit **S**
- Total cholesterol: 216 mg/dL (high) at baseline, 132 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL at baseline, 46 mg/dL at this visit **S**
- LDL cholesterol: 142 mg/dL (high) at baseline, 62 mg/dL at this visit **S**
- Triglycerides: 148 mg/dL at baseline, 120 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 79.4 kg |
| Cardiovascular | Regular rhythm at 68 per minute; blood pressure 126/76 mmHg |
| Abdomen | Pulsatile, non-tender mass above the umbilicus |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension** (I10). At target on amlodipine 5 mg and losartan 100 mg: 126/76 mmHg in the clinic and 124/74 at home. Potassium 4.7 and creatinine 1.10 after the dose increase. **S**
   - Continue both medicines.
   - Metabolic panel every six months.
2. **Atherosclerosis of the abdominal aorta** (I70.0). LDL 62 mg/dL on atorvastatin 40 mg, down 56 percent from 142 and below 70. The panel was drawn at sixteen weeks rather than within twelve; the result shows no harm from the delay. **S**
   - Continue atorvastatin 40 mg and aspirin 81 mg.
   - Lipid panel yearly; standing laboratory orders now placed for every follow-up.
3. **Nicotine dependence, pipe tobacco** (F17.290). Tobacco-free for about fifteen weeks. **S**
   - Step the patch down to 7 mg daily until the six-month visit.
   - Lozenges only as needed.
4. **Infrarenal abdominal aortic aneurysm under surveillance** (I71.43). No symptoms; non-tender. **S**
   - Duplex ultrasound at the six-month visit, with popliteal duplex and ankle-brachial index.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Aneurysm diameter by duplex ultrasound (CT if views are poor) | Every 6 months at 5.0 to 5.4 cm in men; yearly at 4.0 to 4.9 cm | Up to date | 5.0 cm by duplex ultrasound at the sick visit six weeks ago, unchanged; next scan at six months |
| Imaging | CT angiography for baseline anatomy and repair planning | Once at baseline; again when repair is considered | Up to date | Baseline done; repeat only if repair is considered |
| Examination | Femoral and popliteal arteries for a coexisting aneurysm | Once at diagnosis | Up to date | Normal on examination; popliteal duplex planned with the six-month scan |
| Examination | Aneurysm symptoms and tenderness, with the emergency plan reviewed | Every visit | Completed today | No pain or tenderness since the back strain resolved; emergency plan reviewed |
| Referral | Vascular surgery review and shared decision on elective repair | At baseline, then at a threshold change or yearly | Up to date | Shared decision recorded at the four-week visit; review at the six-month scan |
| Examination | Blood pressure, target below 130/80 | Every visit | Completed today | 126/76 mmHg; at target |
| Self-management | Home blood pressure readings | Before each visit while treatment is being adjusted | Completed today | Home average 124/74 |
| Laboratory | Metabolic panel (sodium, potassium, creatinine, eGFR) | 2 to 4 weeks after starting or changing losartan; then every 6 months | Completed today | After the losartan increase: sodium 139, potassium 4.7, creatinine 1.10 mg/dL, eGFR 70; next in six months |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Deferred | Not drawn within the 4 to 12 week window after atorvastatin was started, a deviation from the protocol: no standing order was placed at the four-week visit and no visit fell before twelve weeks. Judging by today's result, no harm resulted. Corrective action: standing laboratory orders are placed at each visit for tests due before the next one |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Completed today | Drawn today at sixteen weeks: total cholesterol 132, HDL 46, LDL 62, triglycerides 120 mg/dL; LDL down 56 percent and below 70 |
| Laboratory | ALT | Once before a statin; then only with symptoms | Not indicated | No muscle or liver symptoms; routine repeat not recommended |
| Laboratory | HbA1c | Yearly | Up to date | 5.6 percent in March; repeat yearly |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 14 mg/g in March; repeat yearly |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | Adherent; no muscle aches |
| Medication safety | Low-dose aspirin: indication and bleeding | Every visit while taking it | Completed today | No bruising, black stools, or bleeding |
| Medication safety | Medication review: avoid fluoroquinolones and anti-inflammatory pain medicines | Every visit | Completed today | Acetaminophen only for the back strain; no anti-inflammatory or fluoroquinolone use |
| Self-management | Tobacco use and cessation support (5 A's, nicotine replacement) | Every visit | Completed today | Tobacco-free about fifteen weeks; patch stepped down to 7 mg |
| Examination | 12-lead ECG | Baseline with hypertension; repeat as indicated | Up to date | Normal at the four-week visit |
| Examination | Ankle-brachial index | Every 2 to 3 years at 65 or older or with a smoking history | Due | With the six-month duplex scan |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Due | To be arranged at the wellness visit |
| Examination | Weight and BMI | Every visit | Completed today | 79.4 kg; BMI 26.8 |

## Goal progress

- Baseline CT angiography and a vascular surgery consultation, with a documented shared decision about repair thresholds, by the four-week visit. Outcome by 1949-04-21: CT angiography two weeks after the first visit; consultation and shared decision at the four-week visit. **S**
- Blood pressure below 130/80 at the clinic and at home by the three-month visit. Outcome by 1949-07-14: 126/76 mmHg in the clinic; home average 124/74 on amlodipine 5 mg and losartan 100 mg. **S**
- LDL cholesterol at least 50 percent lower and below 70 mg/dL by the three-month visit. Outcome by 1949-07-14: LDL 62 mg/dL on atorvastatin 40 mg, down 56 percent from 142. **S**
- Tobacco-free by the three-month visit and still at six months. In progress; target 1949-09-22. **S**
- Repeat duplex ultrasound at six months and set the next interval by diameter. In progress; target 1949-09-22. **S**

## Medication changes

- Stopped: Nicotine 14 mg/24 hour transdermal patch, one patch daily **S**
- Started: Nicotine 7 mg/24 hour transdermal patch, one patch daily **S**

## Guideline basis

- The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm (2018), Society for Vascular Surgery (Journal of Vascular Surgery)
- 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease (2022), American College of Cardiology and American Heart Association (Circulation)
- CMID: Clinical Monitoring Intelligence Database, Hypertension and Hyperlipidemia monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force

## Follow-up

- Annual wellness visit in about six weeks. Six-month surveillance visit with duplex ultrasound, popliteal duplex, and ankle-brachial index. **S**
- Next scheduled visit 1949-08-25: subsequent annual wellness visit. **S**
